Smith and Nephew (UK) moves up orthopaedics league with Acufex
This article was originally published in Clinica
Smith & Nephew (UK) is to acquire Acufex for £90 million ($144 million) cash, giving it an additional £40 million in annual revenues. The proposed acquisition of the American Home Products subsidiary, announced on May 15th, is subject to regulatory approval which could take up to 90 days.
You may also be interested in...
Dr Reddy's is poised to expand its OTC offering in Russia and certain CIS countries by snapping up a basket of allergy brands from India's Glenmark.
Second read-out maintains 94% level of efficacy, with a very early signal that it could outperform Pfizer’s rival mRNA candidate in preventing severe cases.
The French major and Regeneron have racked up another indication for Dupixent with the blockbuster getting approval in Europe to treat children with severe eczema.